Prediction versus Attrition in Drug Discovery & Development By Professor Malcolm Young The research-intensive part of the pharmaceutical industry is facing unusual commercial difficulties, whose elements are now well-known. A substantial number of very valuable drugs have gone, or are about to go, off patent; too few good new premium drugs are coming through to […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!